The end of the second quarter is marking the start of a deal streak for Skadden, Arps, Slate, Meagher & Flom, with the Am Law 100 firm advising San Diego-based Amylin Pharmaceuticals Inc. in connection with its $7 billion sale to pharmaceutical giant Bristol-Myers Squibb Co.
Skadden’s role for Amylin comes on the heels of the firm advising News Corp. on its proposed restructuring into two new publicly traded companies; Anheuser-Busch InBev on its $20.1 billion acquisition of Grupo Modelo; and Dell Inc. on its $2.4 billion acquisition of Quest Software Inc..
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
